Precision BioSciences, an early stage biotech developing off-the-shelf CAR T cell cancer therapies, raised $126 million by offering 7.9 million shares at $16, the midpoint of the $15 to $17 range. At pricing, the company will command a fully diluted market value of $870 million. Precision BioSciences plans to list on the Nasdaq under the symbol DTIL. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as lead managers on the deal.
